You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR072/#1519  Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)

Citation Tools

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR072/#1519  Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Adjei N, Coleman R, Fellman B, et al
PR072/#1519  Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)
International Journal of Gynecologic Cancer 2023;33:A71-A73.